Clinical trials: Gemcitabine
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
This 2 arm study will compare the efficacy and safety of Tarceva plus Avastin, and chemotherapy plus Avastin, in the first-line treatment of patients with advanced non-small cell lung cancer.
- Trial name
- NCT00531960
- Testing
- Erlotinib, Bevacizumab, Standard platinum-based chemotherapy
- Where
- 57 sites in Australia, Belgium and 11 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Nasopharyngeal Carcinoma, Recurrent or Metastatic
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by…
- Trial name
- NCT05294172
- Testing
- KL-A167, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 295 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate [ORR; Cohorts 1,2, 4,and 5] and…
- Conditions
- Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
- Trial name
- GOBLET (NCT07280377)
- Testing
- Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel
- Where
- 15 sites in Germany
- Volunteers
- 122 people
- Sponsor
- Oncolytics Biotech
Non-Small Cell Lung Cancer (NSCLC)
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
- Trial name
- NCT01951157
- Testing
- Docetaxel, Gemcitabine, Lurbinectedin (PM01183)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- PharmaMar
EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
This randomised, controlled, open-label, prospective trial is designed to assess the efficacy and safety of icotinib maintenance therapy after sequential Icotinib plus chemotherapy versus Icotinib maintenance therapy after…
- Trial name
- NCT02194556
- Testing
- Sequential and maintenance icotinib, Maintenance icotinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced or Metastatic Pancreatic Adenocarcinoma
Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine
A dose finding study in locally advanced and/or metastatic pancreatic cancer patients
- Trial name
- NCT00560963
- Testing
- everolimus
- Where
- 5 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Neoplasms
A Study for Participants With Pancreatic Cancer
The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study.
- Trial name
- NCT00839332
- Testing
- LY2603618, Gemcitabine
- Where
- 30 sites in United States, Germany and 4 more
- Volunteers
- 157 people
- Sponsor
- Eli Lilly and Company
Triple Negative Breast Cancer
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
The primary scientific question of interest of this study is whether the combination of ociperlimab, tislelizumab and chemotherapy improves progression-free survival (PFS) compared to the combination of placebo, pembrolizumab and…
- Trial name
- AdvanTIG-211 (NCT05809895)
- Testing
- Ociperlimab, Tislelizumab, Paclitaxel
- Sponsor
- Novartis Pharmaceuticals
Biliary Tract Cancer
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed…
- Trial name
- NCT05065957
- Testing
- D07001-softgel capsules + Xeloda (or TS-1), mFOLFOX
- Where
- 5 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- InnoPharmax Inc.
Recurrent or Metastatic Cervical Cancer
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
This is a randomized, open-label, 3-arm Phase 2 study to evaluate the efficacy and safety of SHR-1210 alone or with SHR-1020 versus physician's choice chemotherapy in recurrent or metastatic cervical cancer patients.
- Trial name
- NCT04680988
- Testing
- SHR-1210, SHR-1020, Physician's choice chemotherapy
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Ductal Adenocarcinoma
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT06492915
- Testing
- Chiauranib, Albumin-paclitaxel Injection, Gemcitabine Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Non-Small-Cell Lung Carcinoma
Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.
The purposes of this study are to determine: How standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer.
- Trial name
- NCT00191620
- Testing
- Gemcitabine, cisplatin
- Where
- 4 sites in Argentina, Brazil and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
To compare the combination of Ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy in premenopausal or perimenopausal patients with advanced or metastatic breast cancer
- Trial name
- RIGHT Choice (NCT03839823)
- Testing
- Docetaxel / Capecitabine, Capecitabine / Vinorelbine, Paclitaxel / Gemcitabine
- Where
- 50 sites in Egypt, India and 11 more
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
- Trial name
- NCT02049905
- Testing
- Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 433 people
- Sponsor
- ImmunityBio, Inc.
Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages.
- Trial name
- Morpheus-panBC (NCT03424005)
- Testing
- Capecitabine, Atezolizumab, Ipatasertib
- Where
- 55 sites in United States, Australia and 7 more
- Volunteers
- 1,132 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Ductal Adenocarcinoma (PDAC)
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel…
- Trial name
- NCT06182072
- Testing
- ProAgio Dose Levels (DL) 1,2,3,4, Gemcitabine, nab paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- ProDa BioTech, LLC
Non Small Cell Lung Carcinoma NSCLC
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal…
- Trial name
- NCT03003962
- Testing
- Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin
- Where
- 92 sites in United States, Australia and 10 more
- Volunteers
- 669 people
- Sponsor
- AstraZeneca
Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer
- Trial name
- NCT01510561
- Testing
- 90Y-hPAM4, 90Y-hPAM4 + gemcitabine
- Where
- 24 sites in United States
- Sponsor
- Gilead Sciences
Triple Negative Breast Neoplasms
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC).
- Trial name
- NCT06841354
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication
- Where
- 283 sites in United States, Argentina and 33 more
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.